• Title of article

    Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution

  • Author/Authors

    Falchi، نويسنده , , Lorenzo and Rege-Cambrin، نويسنده , , Giovanna and Fava، نويسنده , , Carmen and Donti، نويسنده , , Emilio and Luzi، نويسنده , , Debora and Giugliano، نويسنده , , Emilia and Gubbiotti، نويسنده , , Marta and Schippa، نويسنده , , Monica and Liberati، نويسنده , , Anna Marina، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2010
  • Pages
    4
  • From page
    139
  • To page
    142
  • Abstract
    Little is known regarding the activity of tyrosine kinase inhibitors (TKis) on chronic myeloid leukemia (CML) clonal evolution (CE). We treated 10 CE CML patients in either hematologic chronic (8 cases) or accelerated (2 cases) phase with imatinib or second generation TKi. Additional chromosomal abnormalities appeared during the course of disease in seven cases, being present at diagnosis in three. A total of 6/10 (60%) patients achieved complete cytogenetic remission (CCyR) with imatinib in 3–14 months. Major or complete molecular remission (CMR) was obtained in four CCyR patients after 21, 25, 22, and 12 months, as well as in a fifth patient who started nilotinib because of suboptimal response after 75 months of imatinib treatment. One patient received nilotinib due to imatinib intolerance after 56 months of therapy while on CMR, and maintained such status. After a median follow-up of 82 months (range, 3–116), six patients are alive, five of which are in continuous CCyR while one patient is in his third CCyR on dasatinib after relapsing on imatinib and nilotinib. Five patients are in complete (four) or major (one) molecular remission, ongoing at 3, 48, 61, 95, and 96 months, on imatinib (three) or nilotinib (two). Although a small number of patients was studied, our results suggest that long-term cytogenetic and molecular remission can be achieved in CML CE patients with TKis treatment.
  • Journal title
    Cancer Genetics and Cytogenetics
  • Serial Year
    2010
  • Journal title
    Cancer Genetics and Cytogenetics
  • Record number

    1830548